News Agencies Feed 

Amryt Pharma Signs Distributor Agreement With El Seif In Saudi Arabia

Saudi Arabia, November 14, 2017

Amryt Pharma PLC said Monday it has signed a distributor agreement with Faisal Musaed El Seif Saudi Pharmaceutical Co for Amryt's products in Saudi Arabia.

Amryt said the deal covers its Lojuxta and PA101 products, the latter of which is currently in phase 3 trials.

Lojuxta is a treatment for homozygous familial hypercholesterolaemia, a rare, life-limiting disease. AP101 is a potential treatment for life-limiting skin disorder Epidermolysis bullosa and is included in the agreement in anticipation of a successful trial.

Life-limiting means an illness that is expected to cause death.

The company said El Seif, which is an affiliate of El Seif Development Co, is a distributor of medical devices and pharmaceuticals in Saudi Arabia with a 'strong' presence in the rare and orphan diseases drug sector.

Amryt's Chief Executive Joe Wiley said: 'We are delighted to be working with El Seif and to have signed this exclusive distribution agreement which covers Lojuxta and AP101. El Seif has an extensive footprint in Saudi Arabia, and significant breadth and depth of experience and relationships across the institutional and Ministry of Health sectors.

'The signing of this partnership with El Seif is another key milestone for Amryt as we broaden our capability and reach to ensure complete coverage across our key territories.'

Amryt's shares were up 0.7% Monday at 19.25 pence.